Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma
Status:
Completed
Trial end date:
2020-09-03
Target enrollment:
Participant gender:
Summary
This phase 0 trial studies ixazomib citrate in treating patients with glioblastoma that has
spread or returned after period of improvement who are planning to undergo surgery. When
given by mouth, ixazomib may be able to reach tumor cells in the brain. Studying samples of
tissue, blood, and plasma in the laboratory from patients receiving ixazomib may help doctors
learn more about the effects of ixazomib on the cells. It may also help doctors understand
how well patients will respond to treatment.